The drugmaker will partner with the Serum Institute of India to scale production at the Praha site by the end of 2020 and will continue to build antigen production at multiple sites in the U.S. and Asia, Novavax said. FiercePharma
Wednesday, May 27, 2020
Novavax snares $167M buyout to rapidly scale up COVID-19 vaccine manufacturing
The drugmaker will partner with the Serum Institute of India to scale production at the Praha site by the end of 2020 and will continue to build antigen production at multiple sites in the U.S. and Asia, Novavax said. FiercePharma
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment